study, hPTECs stimulated with FFAþBSA increased mitochondrial ROS and decreased mitochondrial membrane potential. These changes were improved with treatment of dh404. CONCLUSIONS: RTAdh404 has a renoprotective effect by protecting against mitochondrial dysfunction in renal tubular epithelial cells. Med. Clinic I, University Hospital RWTH Aachen, Aachen, Germany
INTRODUCTION AND AIMS:
Patients with chronic kidney disease (CKD) on hemodialysis (HD) exhibit an increased cardiovascular risk. METHODS: Fibrinogen was purified from HD patients and healthy control individuals using a calcium dependent IF-1 monoclonal antibody and further investigated using MALDI mass-spectrometric analysis and electron microscopy. RESULTS: Fibrin clot structure parameters and impact on mortality were determined in a prospective cohort of 171 chronic HD patients (59611y, 54% male) using a validated turbidimetric assay. Kaplan Meier analyses revealed that CKD patients with a denser clot structure had an increased mortality risk (log-rank p¼0.004). A multivariate Cox regression model (adjusted for age, diabetes, gender, duration of dialysis, fibrinogen, CRP and complement C3) confirmed the independent mortality risk prediction of denser clots (hazard ratio 43.1, 95% CI, 1.4 -1347; p¼0.032). We detect the posttranslational modification of glycosylation and guanidylation in fibrinogen of HD patients, but in fibrinogen of healthy control we detected no posttranslation modifications display. While purified fibrinogen from healthy controls displayed no posttranslational modifications, fibrinogen from HD patients was glycosylated and guanidylated. Clots made of purified fibrinogen from HD patients exhibited significantly thinner fibres compared to control individuals (6361.9 nm and 7762.2 nm respectively; p<0.001). CONCLUSIONS: Thus, in HD patients a denser clot structure is a potent independent predictor of mortality. Fibrinogen of HD patients is posttranslationally modified resulting in a prothrombotic clot structure with thinner fibrin fibers, which may contribute to the elevated mortality in CKD. Intensive Care Unit, Department of Internal Medicine, Medical University of Graz, Graz, Austria INTRODUCTION AND AIMS: Chronic kidney disease and diabetes mellitus are associated with extensiv media calcification. The calcification of the tunica media is not only driven by systemic factors such as hyperphosphatemia and hyperglycemia, but is also depending on vascular smooth muscle cells. The aim of our study was to investigate the role of autophagy in the pathogenesis of uremic media calcification. METHODS: DBA/2NCrl mice were fed with high phosphate diet (HPD) for 5 or 12 days. DBA2/NrCrl mice on standard chow diet (SCD) were used as controls. To influence autophagy mice were treated intraperitoneally with rapamycin starting on day -3. For our in vitro experiments, mouse muscular smooth muscle cells (MOVAS) were used. The medium was supplemented with ascorbic acid and beta-glycerolphosphate to induce calcification. To influence autophagy, cells were treated with Rapamycin. Aorta samples as well as MOVAS were analyzed using qPCR, Western Blot, histology and calcification. RESULTS: DBA2/NCrl mice on HPD developed a severe vascular calcification and also the cells showed calcification in presence of calcifying medium. qPCR of mouse aortas revealed a significantly higher gene expression of autophagy related genes such as igfbp3 or trp53in and day 5 and 12 on HPD. The protein level of the autophagy marker LC3-I/ II marker was also significantly increased in aortas of mice on HPD. Histologocal staining showed that autophagy is located in the tunica media of the aortas and that it is increasing with the on HPD. Rapamycin treatment further increased autophagy in vivo and in vitro. Rapamycin treatment resulted in a significant decrease of vascular calcification in vivo and in vitro. Furthermore, Rapamycin-treated mice survived longer compared to vehicle-treated controls. CONCLUSIONS: These findings indicate that autophagy plays an important role in the development of uremic media calcification. Furthemore, induction of autophagy by Rapamycin protects cells and mice from uremic media calcification. 
Chronic kidney disease (CKD) is characterized by accumulation of uremic toxins especially, some protein-bound uremic toxins as p-cresyl sulfate which are considered to be associated with an increase of cardiovascular (CV) disease and mortality. 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) is a metabolite of furan fatty acid and is increased in patients consuming fish or fish oil. Blood CMPF is known to be elevated in CKD and it is poorly removed by haemodialysis (HD). CMPF directly interacts with free oxygen radicals, which can induce cell damages. Therefore, CMPF has been reported to inhibit erythropoiesis, contributes to the development of thyroid abnormalities and impair neurological function. The putative role of CMPF in beta-cell dysfunction and metabolic syndrome is still under debate. The aim of the present study is to investigate potential association between CMPF levels and i) biochemical and nutritional parameters that are disturbed in HD, (ii) CV events and (iii) mortality. METHODS: 252 patients undergoing maintenance HD in Lyon, France, were included. 14 patients were excluded because of a lack of serum. At the inclusion, we performed a dosage of serum CMPF by HPLC-UV technique and routine clinical biochemistry tests. Body composition parameters including the lean tissue index (LTI, kg/m2) and fat tissue index (FTI, kg/m2) were measured using a bioimpedance spectroscopy method (BCMV R , Fresenius Medical Care, Germany). The enrolled patients were prospectively monitored for CV events and mortality. During the mean study period of 937 days, 48 patients died and 56 suffered a CV events. RESULTS: Median of serum CMPF was 2.55 mg/l [1.00 -5.23]. Kaplan-Meier analysis showed no significant correlation between elevated serum CMPF and an increase of allmortality risk (log rank, p¼0.42), CV mortality risk (log rank, p¼0.21) or CV events risk (log rank, p¼0. CONCLUSIONS: This is the first largest prospective cohort of serum CMPF dosage in HD patients. Our data suggest that CMPF accumulation is not associated to CV risk in this population. Moreover, in this study, CMPF accumulation is not associated with metabolic disturbances. However surprisingly, CMPF is associated with a better nutritional status, consistent with the hypothesis that CMPF would be a marker of healthy diet and omega 3 intakes. Further studies are needed to understand the role of CMPF in CKD and HD. 
